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Summary
Polychlorinated biphenyls (PCBs) and their hydroxyl-
ated metabolites (OH-PCBs) are known to bind to
transthyretin (TTR) in vitro, possibly explaining their
bioaccumulation, rodent toxicity, and presumed hu-
man toxicity. Herein, we show that several OH-PCBs
bind selectively to TTR in blood plasma; however,
only one of the PCBs tested binds TTR in plasma.
Some of the OH-PCBs displace thyroid hormone (T4)
from TTR, rationalizing the toxicity observed in ro-
dents, where TTR is the major T4 transporter. Thyroid
binding globulin and albumin are the major T4 carri-
ers in humans, making it unlikely that enough T4 could
be displaced from TTR to be toxic. OH-PCBs are ex-
cellent TTR amyloidogenesis inhibitors in vitro be-
cause they bind to the TTR tetramer, imparting kinetic
stability under amyloidogenic denaturing conditions.
Four OH-PCB/TTR cocrystal structures provide fur-
ther insight into inhibitor binding interactions.
Introduction
Polychlorinated biphenyls (PCBs) are known persistent
environmental pollutants [1] that are reported to be toxic
to rodents and possibly humans [2–4]. The longevity of
these compounds in the environment is due to their
slow degradation and high lipophilicity, which allows
them to bioaccumulate and concentrate as they move
up the food chain [2]. Hydroxylated PCBs (OH-PCBs)
are metabolites formed by oxidation of PCBs by the
P450 monooxygenases [5]. Definitive data on the toxic-
ity of individual PCB compounds in humans is difficult
to find due to the fact that the commercially available
PCBs are generally mixtures that contain many different
isomers as well as trace amounts of known toxins, e.g.,
chlorinated dibenzofurans [2]. However, the toxicity of
several purified PCBs has been demonstrated in labo-
ratory animals. Bone loss [6], immunologic toxicity [4],
neurotoxicity [7, 8], and lowered thyroid hormone
levels, in addition to the estrogenicity of the OH-PCBs
[9, 10] are associated with the administration of these
compounds.
Numerous studies demonstrate that PCBs and OH-*Correspondence: jkelly@scripps.eduPCBs bind to transthyretin (TTR) in vitro [11–17]. Trans-
thyretin is a 127 residue β sheet-rich tetrameric protein
present in human blood plasma (3.6 M) and cerebro-
spinal fluid (CSF) (0.36 M). TTR has two C2-intercon-
vertible thyroxine (T4) binding sites and four orthogonal
holo-retinol binding protein binding sites, of which a
maximum of two can be occupied due to overlapping
footprints. It has been hypothesized that PCB and OH-
PCB displacement of T4 from TTR causes lowered T4
levels in exposed rats and mice, as TTR is the primary
T4 transporter in rodents. In human plasma, only 10%–
15% of T4 is TTR bound because thyroxine binding
globulin (TBG) and albumin are the main carriers [18–
20]; in fact, less than 1% of human plasma TTR (z3.6
M) has T4 bound to it. It has been suggested that TTR
is the protein target in human blood that contributes to
the persistence of the OH-PCBs in exposed individuals
[5]. While numerous reports implicate TTR as a PCB
binding protein in vivo [21–25], there is no definitive evi-
dence that PCBs bind to transthyretin in plasma. We
have developed an antibody capture method that can
be used to place a lower limit on the binding stoichiom-
etry of small molecules to TTR in biological fluids [26].
The TTR binding stoichiometry of PCBs and OH-PCBs
to human plasma TTR was evaluated herein.
Post-secretion amyloidogenesis of plasma TTR requir-
ing rate-limiting tetramer dissociation, monomer misfold-
ing, and misassembly putatively causes senile systemic
amyloidosis, familial amyloid cardiomyopathy, and the
familial amyloid polyneuropathies, a subset of which
exhibit CNS symptoms [27–36]. Several structurally di-
verse groups of compounds have been identified by
screening and structure-based design that inhibit TTR
amyloid formation in vitro [34, 37–48]. Herein, we de-
monstrate that several OH-PCBs bind selectively to
TTR in human plasma and inhibit amyloid fibril forma-
tion through tetramer stabilization, leading to partial or
complete kinetic stabilization of the native state [34].
Four representative TTR•(OH-PCB)2 complexes were
characterized by X-ray crystallography to better under-
stand the molecular basis for binding and to provide
the basis for the design of optimized TTR amyloidogen-
esis inhibitors.
Results
Binding Selectivity of PCBs and OH-PCBs
for Transthyretin in Human Blood Plasma
The binding selectivity of eight PCBs (compounds 1–8,
Figure 1A), reported to displace thyroid hormone from
TTR with an IC50 of less than 50 nM [17], and 14 OH-
PCBs (compounds 9–22, Figure 1B), known PCB me-
tabolites that are reported to bind to TTR [12, 14–16,
49] or lower thyroxine levels in mice or rats [22, 50],
was evaluated using an established method [26]. Lower
limits on PCB binding stoichiometry to TTR in plasma
were established using polyclonal TTR antibodies co-
valently attached to a Sepharose resin that was mixed
with human blood plasma pretreated with PCB or OH-
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bFigure 1. Compounds Evaluated in This Study
sStructures of the PCBs (A) and OH-PCBs (B) screened for binding
ato TTR in blood plasma.
t
pPCB (10.8 M). After washing with 0.05% saponin in
2buffer and just pH 8 buffer, the PCB or OH-PCB binding
sstoichiometry to TTR (z5 M) was evaluated by re-
sverse phase HPLC [26].
wUp to two PCBs can bind to the two identical thyroid
hormone binding sites in the TTR tetramer. Except for
TPCBs 1 and 3, the remaining nonhydroxylated PCBs
Tdisplayed relatively low binding selectivity for plasma
TTTR (<0.2; Table 1). In contrast, the OH-PCBs showed
t
T
aTable 1. Binding Stoichiometry of PCBs and OH-PCBs
to Transthyretin in Human Plasma and Blood, Uncorrected e
for Losses that May Occur during Five Wash Steps w
dEquivalents Bound Equivalents Bound
gCompound (Plasma) (Blood)
a1 0.62 ± 0.12 ND
t2 0.18 ± 0.03 ND
m3 1.50 ± 0.42 ND
4 0.05 ± 0.04 ND d
5 0.06 ± 0.04 ND T
6 0.19 ± 0.11 ND t
7 no binding ND
18 no binding ND
o9 0.83 ± 0.19 0.57
a10 0.96 ± 0.09 0.93
11 1.12 ± 0.22 1.20 p
12 1.23 ± 0.24 1.47 [
13 0.84 ± 0.24 0.86 w
14 0.81 ± 0.29 0.73
15 0.70 ± 0.17 0.56
B16 1.86 ± 0.14 ND
17 1.63 ± 0.05 ND P
18 1.36 ± 0.21 ND O
19 1.48 ± 0.16 1.55 T
20 1.02 ± 0.09 0.86 [21 1.40 ± 0.22 1.33
a22 1.67 ± 0.40 1.69
m
ND, not determined.
pood to excellent binding selectivity for plasma TTR
0.7–1.9 stoichiometry; Table 1). Several of the hydrox-
lated PCBs (e.g., 16, 17, 19, and 22) exhibit a binding
toichiometry exceeding 1.5. The binding selectivity of
H-PCBs in blood is similar to that observed in plasma
Table 1); hence, erythrocyte membranes do not signifi-
antly sequester the OH-PCBs studied.
The antibody capture of the TTR•PCB complex un-
erestimates the PCB binding stoichiometry in plasma
wing to PCB dissociation from TTR during the five
ash steps, three with 0.05% saponin in pH 8 buffer
nd two with pH 8 buffer. Selected PCBs and OH-PCBs
10.8 M) were incubated with recombinant TTR (3.6 M)
o evaluate the stoichiometry of small molecule bound
o immobilized TTR after each wash step. Stoichiome-
ry decreased by 10%–17% for PCB 2 and OH-PCB 18
fter five washes (Figure 2A), whereas that of PCB 4
ecreased by 45%. Quantification of wash-associated
osses allows one to estimate the true binding stoichi-
metry of PCBs and OH-PCBs in plasma; however, un-
orrected data are reported in Table 1, representing the
ower limit of the binding stoichiometry in plasma or
lood. Furthermore, a good correlation between the final
toichiometry of OH-PCB bound to recombinant TTR
nd the amount bound to TTR in plasma indicates that
he compound is a highly selective TTR binder in
lasma (after five wash steps), e.g., OH-PCB 18 (Figure
B). In contrast, PCBs 2 and 4 exhibit a higher binding
toichiometry to TTR in buffer than in plasma, strongly
uggesting that they bind to competitor protein(s) as
ell as TTR in plasma (Figure 2B).
TR Amyloid Fibril Inhibition by Hydroxylated PCBs
he ability of OH-PCBs and PCB 3 (3.6 M) to inhibit
TR amyloidogenesis in vitro was evaluated because
hese compounds exhibit good binding selectivity to
TR in blood. TTR secreted into blood from the liver
ppears to be the source of TTR amyloid in all diseases
xcept the rare CNS disorders. While it is not yet clear
here or how amyloid is formed in humans, acidic con-
itions are effective in converting nearly all amyloido-
enic peptides and proteins into amyloid and/or related
ggregates. Hence, acid-mediated (pH 4.4) fibril forma-
ion monitored by turbidity [38, 51] was employed to
onitor the effectiveness of the PCBs as inhibitors. Hy-
roxylated PCBs and PCB 3 were highly efficacious as
TR fibril inhibitors (Figure 3). At an inhibitor concentra-
ion equal to the WT TTR concentration (3.6 M), only
2%–50% of the normal amount of fibril formation was
bserved after a 72 hr incubation period. The activity
t the lower end of this range is equivalent to that dis-
layed by the best fibril inhibitors discovered to date
40, 42–44, 46–48], such as flufenamic acid [51], which
as included as a positive control.
inding of OH-PCB 18 to TTR
revious mass spectrometry experiments suggest that
H-PCB 18 exhibits positively cooperative binding to
TR’s two C2-related thyroid hormone binding sites
52]. When substoichiometric (<1:1) amounts of 18 are
dded to TTR, the predominant species observed in the
ass spectrometer are apo-TTR and the TTR•182 com-
lex, consistent with positively cooperative binding
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lected PCBs and OH-PCBs during the Five
Wash Steps of the Immunocapture Method
and Their Relative Binding Selectivities to
TTR in Plasma and in Buffer
(A) Loss of PCBs 2, 4, and OH-PCB 18 during
each wash step of the immunocapture
method. The binding stoichiometry of the
compounds after each step is shown.
(B) Correlation of the measured binding stoi-
chiometry in plasma with the measured bind-
ing stoichiometry to recombinant TTR for selected PCBs and OH-PCB 18 using the immunoprecipitation method. The diagonal line represents
a 1:1 correlation between the in vitro and plasma binding stoichiometries.[52]. The TTR binding characteristics of 18 are in con-
trast to those exhibited by numerous other TTR amyloid
fibril inhibitors that bind with negative cooperativity.
Isothermal titration calorimetry studies carried out un-
der physiological conditions reveal that the binding of
OH-PCB 18 to WT TTR fits best to a model where the
dissociation constants are identical (Kds = 3.2 ± 1.8
nM). This result is not in contrast with positively coop-
erative binding, as one cannot achieve a low enough
TTR concentration to probe positive cooperativity be-
cause of insufficient heat release. Attempts to fit the
collected data to models of positively or negatively co-
operative binding yielded poor fits.
Cocrystal Structures of OH-PCBs 12, 16, 17, and 18
Crystals of WT TTR bound by two equivalents of OH-
PCBs 12, 16, 17, and 18 were obtained by soaking TTR
crystals with a 10-fold excess of inhibitor for 4 weeks.
X-ray structures were then solved for each of the com-
plexes (Table 2; Figure 4). The TTR dimer within the
crystallographic asymmetric unit forms half of the two
ligand binding pockets. Because both binding sites are
bisected by the same 2-fold axis of symmetry, two sym-
metry equivalent binding modes of the inhibitors are
typically observed (green and gray stick representa-
tions in Figure 4) [43, 44, 47, 48, 51]. Each TTR binding
site can be subdivided into inner and outer cavities.
These cavities comprise three so-called halogen bind-
ing pockets (HBPs) because they are occupied by the
iodines on the two aromatic rings of thyroxine. HBP 3
and 3# are located deep within the inner binding cavity,
HBP 2 and 2# define the boundary between the inner and Thr119 adopt alternative conformations by rotation
Figure 3. OH-PCB Inhibition of TTR Fibril
Formation
OH-PCB inhibition (3.6 M) of acid-mediated
TTR (3.6 M) fibril formation (pH 4.4) in vitro.
TTR amyloidogenesis in the absence of in-
hibitor is assigned to be 100%. Flufenamic
acid (Flu 3.6 M) is included as a positive
control.and outer binding cavity, whereas HBP 1 and 1# are
located near the periphery of outer binding cavity (Fig-
ure 4). The cocrystal structures reveal that the C-C
bond connecting the two aromatic rings of the OH-PCB
is nearly centered on the 2-fold symmetry axis, giving
the appearance of a single binding conformation. The
dihedral angle between two phenyl rings is 59° for 12,
37° for both 16 and 17, and 44° for 18. All of the OH-
PCBs occupy similar positions in the inner and outer
binding pockets. The van der Waals complimentarity
of the biaryl ring system facilitates several intersubunit
interactions involving residues 108, 119, and 121 in the
subunits comprising each binding site. Several of the
substituents on the phenyl rings are off-axis and can
be modeled in multiple positions within the observed
electron density.
OH-PCB 18 Bound to TTR
The 1.8 Å X-ray crystal structure of the TTR•182 com-
plex demonstrates that the inhibitor has excellent steric
complementarity with the TTR binding site (Figure 4A).
Symmetrical inhibitor 18 makes hydrophobic contacts
with the side chains of Leu17 and Ala108. Molecular
mechanics (Insight II, Accelrys) indicates that the un-
bound preferred conformation of 18 is very close to its
bound structure. The refined structure defines direct
and water-mediated electrostatic interactions that con-
tribute to high-affinity binding of 18. One of the 3-Cl,
4-OH, 5-Cl identically substituted aromatic rings occu-
pies the inner binding pocket, its chlorine substituents
projecting into HBP 3 and 3#. The side chains of Ser117
Chemistry & Biology
1722Table 2. Refinement Statistics for OH-PCB•TTR Crystal Structures
12 16 17 18
Unit cell parameters (Å) 42.62, 85.17, 64.61 43.68, 85.46, 64.24 43.68, 85.46, 64.24 43.68, 85.46, 64.24
Space group P21212 P21212 P21212 P21212
Resolution (Å) 27.0–2.1 9.0–1.85 9.0–1.85 10.0–1.8
No. of unique reflections 14,176 18,746 19,133 21,209
measured
Completeness (%) 98.6/98.2 90.5/87.5 89.2/92.0 92.6/92.0
(overall/outer shell)
Rsym (overall/outer shell) 0.03/0.23 0.03/0.25 0.04/0.18 0.04/0.17
Refinement Statistics
Resolution (Å) 27.0–2.1 9.0–1.85 9.0–1.85 10.0–1.8
R factor/Rfree (%) 23.5/26.2 21.2/24.5 19.5/23.0 18.7/22.5about their Cα-Cβ bonds as discerned by the unbiased o
ielectron density maps (Figure 4A). The side chain of
Ser117 adopts all three low energy rotamer conforma- t
htions as discerned by the distribution of electron den-
sity. Interestingly, two water molecules are located in p
Hbetween the adjacent Ser117 residues at the 2-fold axis
with 50% occupancy, facilitating a network of hydrogen t
mbonds connecting the Ser117 residues, the nearby water
molecules, and the phenol functionality of 18 (Figure L
4A). The two conformations of Thr119 confer electro-
static interactions that further stabilize the binding of O
T18. In one conformation, the γ-O atom of Thr119 forms
electrostatic interactions with the chlorine (3.4 Å) and a i
thydrogen bond with the side chain of Ser117 (2.6 Å),
while in the second conformation it forms a hydrogen w
dbond with a water molecule that also hydrogen bonds
with three groups from TTR. s
tThe other identically substituted ring occupies the hus it is not possible to position the para-OH and para-
Figure 4. Cocrystal Structures of Selected
OH-PCBs Bound to TTR
Depiction of compounds 18 (A), 16 (B), 17
(C), and 12 (D) bound to one of the two bind-
ing pockets of TTR shown as a surface. The
center of the TTR tetramer (inner binding
pocket) is at the bottom of each figure, and
the solvent entrance to the pocket (outer
binding pocket) is at the top. The two sym-
metry equivalent conformations of the small
molecule are shown in gray and green. The
halogen binding pockets are labeled as
HBPs. Leu17 (A) is not shown for clarity.uter TTR binding pocket with its halogens projecting
nto HBPs 1 and 1#. It is not clear what role, if any,
he hydroxyl substituent of 18 plays in binding, as the
ydroxyl group does not form any H bonds with the
rotein or ordered solvent in the outer binding pocket.
owever, the Cl substituents appended to the ring in
he outer binding pocket interact with an ordered water
olecule that H bonds to the -ammonium group of
ys15.
H-PCB 16 Bound to TTR
he 3-Cl, 4-OH, 5-Cl trisubstituted phenolic ring of 16
s oriented into the inner binding site of TTR, making
he same electrostatic and hydrophobic interactions
ith TTR that this ring does in the TTR•182 structure
escribed above (Figures 4A and 4B). The electron den-
ity of 16, like that of OH-PCB 18, is symmetric, and
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1723Cl unambiguously based upon the electron density
map. The unbiased electron density map is consistent
with three rotomer conformations of Ser117, two con-
formations of Thr119, and contains two water mole-
cules in between the Ser117 residues, analogous to the
TTR•182 structure, apparently for the same function
described above. The 3,4-dichlorinated aromatic ring
occupies the outer binding pocket, with the halogen
directed into HBP-1 or 1#, depending upon which sym-
metry equivalent binding mode is being considered
(Figure 4B).
OH-PCB 17 Bound to TTR
Inhibitor 17 binds with its 3-Cl, 4-OH, 5-Cl substituted
aryl ring oriented into the inner binding pocket, utilizing
the same interactions that this ring uses in the TTR•162
and TTR•182 structures described above (Figure 4C).
The multiple conformations of Ser117, Thr119, and the
two conserved water molecules characterizing the struc-
tures described above are also features of the TTR•172
complex, presumably for the same reasons. The 2,3,4-
trichlorinated ring occupies the outer binding pocket,
utilizing interactions with HBP-1 and HBP-2 or the sym-
metry equivalents HBP1# and HBP-2#.
OH-PCB 12 Bound to TTR
Biaryl 12 places its 3-Cl, 4-OH substituted aryl ring in
the outer binding pocket, with the chlorine substituent
interacting with HBP-1 or 1# (Figure 4D), in contrast to
the structures of TTR•162 and TTR•172, where the phe-
nol-substituted ring is located in the inner binding
pocket. The hydroxyl group (probably in the ionized
form) is within hydrogen bonding distance of the Lys15
side chains, justifying its orientation in the outer bind-
ing site. The tetrachlorinated ring is placed in the inner
binding pocket wherein the halogens are oriented in
HBPs 3, 3# and 2#, or 3#, 3 and 2. The Ser117 and
Thr119 side chains adopt conformations that are iden-
tical to those found in the apo-TTR structure, unlike the
situation in 16, 17, and 18.
Discussion
Although it has been known for some time that PCBs
and OH-PCBs bind to TTR in vitro [12, 14–17, 49], there
has been very little direct evidence that these compounds
can bind TTR selectively in plasma or CSF in vivo. Most
in vivo studies have monitored this interaction indirectly
through the levels of thyroid hormone [13, 23, 53–58],
which is problematic because albumin binding can also
displace T4. The only studies showing evidence of OH-
PCB binding to TTR in plasma utilized a radiolabeled
OH-PCB and reported that 16 migrated at the position
of TTR on a native polyacrylamide gel of whole plasma
[22, 24, 25].
Herein, we evaluated eight PCBs previously reported
to displace T4 with an IC50 of less than 50 nM and show
that only 1 and 3 bind to TTR with an appreciable stoi-
chiometry in human plasma (Table 1). In contrast, all 14
OH-PCBs previously reported to bind to TTR exhibited
excellent binding selectivity to TTR in plasma, with nine
exhibiting binding stoichiometries exceeding 1 (Table1). This is consistent with the observation that OH-
PCBs are observed primarily in plasma and appear to
be selectively retained there, as opposed to sequestra-
tion by lipids and other tissues where PCBs typically
accumulate [5]. The OH-PCBs also bind selectively to
TTR in whole blood, consistent with the idea that they
do not partition into lipid membranes of erythrocytes
(Table 1).
The amount of PCB (or OH-PCB) that washes off of
the antibody•TTR•PCB complex during the five wash-
ing steps of the antibody capture method was eval-
uated using recombinant WT TTR (Figure 2) [26]. The
extent of wash-associated PCB dissociation is mole-
cule specific. Some compounds exhibit high binding
stoichiometry after the washes, consistent with high ini-
tial binding selectivity and low wash-associated losses,
implying a slow dissociation rate. Compounds exhibit-
ing low binding stoichiometry fall into at least two cate-
gories: those with high initial binding stoichiometry ex-
hibiting significant wash-associated losses or those
displaying low initial binding stoichiometry without sig-
nificant wash-associated losses, the latter scenario
applicable to compounds that bind with high affinity to
TTR but with even higher affinity to another plasma pro-
tein(s). PCBs 2 and 4 both exhibit low post-wash bind-
ing stoichiometry to recombinant TTR (Figure 2). Forty-
five percent of PCB 4 was lost due to washes, whereas
PCB 2 simply exhibits poor initial binding stoichiometry
with minimal wash-associated losses (10%). The post-
wash stoichiometry values reported in Table 1 reflect a
lower limit of the amount of PCB that is initially bound
in plasma because they are not corrected for wash-
associated losses. Compounds like OH-PCB 18, which
are characterized by high post-wash binding stoichi-
ometry, must exhibit high binding affinity selectivity and
a slow dissociation rate, consistent with the slow off-
rate observed [34]. These are the type of molecules that
are the most useful native state stabilizers [34, 37].
In addition to their high binding selectivity to plasma
TTR, the OH-PCBs and PCB 3 also display excellent
inhibition of TTR fibril formation in vitro (Figure 3). The
efficacy of inhibitors 14, 15, and 18 are among the high-
est observed to date at equimolar inhibitor and TTR
concentration (3.6 M). This is likely attributable to their
high binding affinity and their slow dissociation rates
and their non- or positively cooperative TTR binding
properties, which are unusual [34, 37, 44, 51, 52, 59].
The calorimetric data do not allow one to distinguish
between positively and noncooperative binding; how-
ever, we will assume the latter, which seems to better
explain the data reported below. The nM Kds exhibited
by the best inhibitor, OH-PCB 18, dictate that the native
state of TTR will be stabilized by >3 kcal/mol. Selective
ground state stabilization by 18 relative to the dissocia-
tive transition state raises the tetramer dissociation
barrier substantially, such that the tetramer cannot dis-
sociate on a biologically relevant timescale [34]. Since
tetramer dissociation is required for amyloidogenicity,
kinetic stabilization of the native state prevents aggre-
gation. Kinetic stabilization of the native state mediated
by binding of 18 was confirmed by the dramatically
slowed tetramer dissociation rates in 6 M urea and
sluggish amyloidogenicity at pH 4.4 [34]. We propose
that the noncooperative binding of OH-PCB 18 (3.6 M)
Chemistry & Biology
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lraises the kinetic barrier of dissociation by selective
cstabilization of the ground state over the dissociative
>transition state [34]. In other words, kinetic stabilization
gof TTR by the binding of 18 prevents 2/3 of a 3.6 M
sTTR sample from being amyloidogenic at pH 4.4 be-
lcause TTR•18 and TTR•182 are incompetent to form
gamyloid; the remainder of TTR (z1.18 M) forms amy-
mloid very inefficiently because of its low concentration
m[34, 60]. The dissociation rates of the best OH-PCB in-
whibitors may also be slower than expected because of
pTTR structural annealing around the OH-PCB, but this
mhas not yet been evaluated as carefully as required. At
ea minimum, these compounds provide guidance for the
Tsynthesis of exceptional inhibitors or may themselves
iprove useful as inhibitors, depending on their toxicity
bprofile.
OThe structures of OH-PCBs 12, 16, 17, and 18 bound
uto TTR reveal that these biaryls generally bind along
tthe crystallographic 2-fold symmetry axis. The dihedral
aangle between the two rings ranges fromw40°–60°, al-
rlowing the halogen binding pockets on two neighboring
7subunits to be engaged simultaneously, leading to sta-
tbilization of the tetrameric quaternary structural inter-
sface. For example, hydroxylated PCB 18 has optimal
structural complimentarity with TTR, as its chlorines are
t
able to bind to HBPs 1 and 1# as well as 3 and 3# simul-
i
taneously.
r
The orientation of the phenolic ring into the inner
c
binding pocket appears to play an important role in that h
it enables a water-mediated hydrogen bonding network t
to form between it and neighboring TTR subunits, f
which presumably further stabilizes the native quater- t
nary structure of TTR. An H-bonding network involving s
the three staggered conformations of Ser117, the phe-
nolic group of the inhibitor, and the two conserved
water molecules creates an electrostatic network that S
interconnects the two subunits that form the PCB bind-
ing site. In contrast, this network of electrostatic in- H
teractions is absent in the 122•TTR complex, in which n
the hydroxyl substituted phenyl ring is oriented in the s
outer binding pocket. Therefore, Ser117 and Thr119 in M
the inner binding pocket adopt apo side chain confor- m
mations in the 122•TTR structure. While there are differ- t
ences in the TTR•OH-PCB cocrystal structures, these i
cannot be used alone to explain selectivity, as binding y
to proteins in addition to TTR must also be considered. O
Surprisingly, the toxicity of OH-PCBs is not well i
established in the literature. In a variety of in vitro and t
animal studies, OH-PCBs appear to be either mildly t
estrogenic [10, 61–63] or antiestrogenic [7, 64–66]. Hy- o
droxylated PCBs are also potent inhibitors of estro- t
gen sulfotransferase activities and specifically inhibit b
SULT1E1 [67, 68]. It has been suggested that this inhibi- i
tory response may increase free 17b-estradiol levels, c
thereby indirectly enhancing estrogenic activity. Hy- o
droxylated PCBs also inhibit sulfation and glucuronida- T
tion of benzo[a]pyrene [69] and exhibit weak thyroid i
hormone-like activity in a yeast two-hybrid assay [70]. a
Other toxicity mechanisms have been suggested [67, d
71], and there are also reports of decreased thyroid hor- t
nmone levels in animals exposed to these compounds.he suggestion that OH-PCB binding to TTR lowers T4
evels and that lowered T4 levels reflects small mole-
ule TTR binding is difficult to directly support. Since
85% of T4 is carried by albumin and thyroid binding
lobulin, the displacement of T4 from these proteins
eems more likely to be the cause of the lowered T4
evels in individuals exposed to PCBs. Thyroid binding
lobulin has the highest affinity for thyroxine and is a
ain carrier in humans [72], but it is not present in
any lower mammals, including rats and mice [73],
here many of the toxicological profiles of these com-
ounds have been studied. Thus, in these species it is
ore likely that compounds binding to TTR will have an
ffect on the overall binding, transport, and levels of
4. Data showing binding of PCBs to TBG suggest little
nteraction, with the exception of one or two weakly
inding compounds [15, 16]. Therefore, the effect of
H-PCBs on human thyroid levels should be minimal
nless they bind to albumin. There are also reports that
hese compounds may interfere with thyroid hormone
ctivation [74] or are associated with an increase in the
ate of sulfation and therefore inactivation of T4 [75,
6]. OH-PCBs could also bind to other thyroid hormone
argets including thyroid hormone receptors, which
eems reasonable given the structural analogy with T4.
It is clear that little is established regarding OH-PCB
oxicity, especially in humans. The toxicology in rodents
s expected to be more severe, owing to the primary
oles of albumin and TTR as the transporters. What is
lear is that OH-PCBs exhibit excellent activity as in-
ibitors of transthyretin fibril formation, suggesting that
his class of compounds has the potential to be useful
or the inhibition of amyloid fibril formation, provided
hat the toxicity of these compounds can be under-
tood [77].
ignificance
erein, we demonstrate that hydroxylated polychlori-
ated biphenyls (OH-PCBs) bind with high affinity and
electivity to transthyretin in plasma and in blood.
any of the OH-PCBs are excellent amyloid fibril for-
ation inhibitors in vitro owing to their ability to bind
o the native state of transthyretin, kinetically stabiliz-
ng the tetramer against dissociation required for am-
loidogenesis. X-ray cocrystal structures reveal that
H-PCBs make hydrophobic and electrostatic bridg-
ng interactions between the subunits that stabilize
he native tetrameric state of transthyretin. Moreover,
he best OH-PCB inhibitor binds non- or positively co-
peratively to the two thyroxine binding sites within
ransthyretin, which seems to be an important attri-
ute of an exceptional inhibitor, unlike the majority of
nhibitors that bind with negative cooperativity. These
ompounds may be useful in humans if the toxicity
f this class of compounds can be better understood.
he administration of transthyretin amyloidogenesis
nhibitors like the ones described within to transgenic
nimals and ultimately to humans will allow us to vali-
ate or disprove the amyloid hypothesis, the idea that
he process of amyloid fibril formation causes the
eurodegeneration characteristic of these disorders.
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Transthyretin Antibody Purification and Conjugation
to Sepharose
Antibodies were produced, purified, and coupled to Sepharose as
reported [26]. The resin was stored as a 1:1 slurry in TSA (10 mM
Tris [pH 8.0]/140 mM NaCl/0.025% NaN3). Quenched Sepharose
was prepared by coupling 200 mM Tris (pH 8.0) to the resin instead
of the antibody.
Human Plasma Preparation
Whole blood was drawn from healthy volunteers at the Scripps
General Clinical Research Center’s Normal Blood-Drawing Pro-
gram and transferred to 50 ml conical tubes. The tubes were centri-
fuged (1730 × g) in a Sorvall RT7 benchtop centrifuge equipped
with a swinging bucket rotor for 10 min at 25°C. The plasma super-
natant was removed and centrifuged again for 10 min to remove
the remaining cells. Sodium azide was added to give a 0.05% solu-
tion. The plasma was stored at 4°C until used.
Immunoprecipitation of Transthyretin and Bound PCBs
A 2 ml tube was filled with 1.5 ml of human blood plasma and 7.5
µl of a 2.16 mM DMSO solution of the PCB under evaluation. This
solution was incubated at 37°C for 24 hr. A 1:1 resin/TSA slurry (187
l) of quenched Sepharose was added to the solution and gently
rocked at 4°C for 1 hr. The solution was centrifuged (16,000 × g), and
the supernatant was divided into three aliquots of 400 µl each.
These were each added to 200 µl of a 1:1 resin/TSA slurry of the
anti-transthyretin antibody-conjugated Sepharose and slowly rocked
at 4°C for 20 min. The samples were centrifuged (16,000 × g), and the
supernatant was removed. The resin was washed with 1 ml TSA/
0.05% Saponin (Acros) (3× 10 min) at 4°C and additionally with 1 ml
TSA (2× 10 min) at 4°C. The samples were centrifuged (16,000 × g),
and the final wash was removed. One hundred fifty-five microliters
of 100 mM triethylamine (pH 11.5) was added to the resin to elute
the TTR and bound small molecules from the antibodies. Following
gentle rocking at 4°C for 30 min, the samples were centrifuged
(16,000 × g), and 145 µl of the supernatant, containing TTR and
inhibitor, was removed.
HPLC Analysis and Quantification of Transthyretin
and Bound PCBs
The supernatant remaining after centrifugation of the TTR antibody
beads (145 l) (described directly above) was loaded onto a Waters
71P autosampler. A 135 µl injection of each sample was separated
on a Keystone 3 cm C18 reverse phase column utilizing a 40%–
100% B gradient over 8 min (A, 94.8% H2O/5% acetonitrile/0.2%
TFA; B, 94.8% acetonitrile/5% H2O/0.2% TFA) controlled by a
Waters 600E multisolvent delivery system. Detection was accom-
plished at 280 nm with a Waters 486 tunable absorbance detector,
and the peaks were integrated to give the area of both TTR and the
small molecule. In order to determine the quantity of each species,
known amounts of tetrameric TTR or PCB were injected onto the
HPLC. The peaks were integrated to create calibration curves from
linear regressions of the data using Kaleidagraph (Synergy Soft-
ware). The calibration curves were used to determine the number
of moles of each species present in the plasma samples. The ratio
of small molecule to protein was calculated to yield the stoichiome-
try of small molecule bound to TTR in plasma.
Transthyretin Amyloid Fibril Formation Assay
Potential inhibitors were dissolved in DMSO at a concentration of
720 M. Five microliters of a solution of the compound being eval-
uated was added to 0.5 ml of a 7.2 M TTR solution in 10 mM
phosphate (pH 7.6), 100 mM KCl, 1 mM EDTA buffer, allowing the
compound to incubate with TTR for 30 min. Four hundred ninety-
five microliters of 0.2 mM acetate buffer (pH 4.2), 100 mM KCl, 1 mM
EDTA was added to yield final TTR and inhibitor concentrations of
3.6 M each and a final pH of 4.4. The mixture was incubated at
37°C for 72 hr, after which the tubes were vortexed for 3 s, and the
optical density was measured at 400 nm. The extent of fibril forma-
tion was determined by normalizing each optical density by that of
TTR without inhibitor, defined to be 100% fibril formation. Control
solutions of each compound in the absence of TTR were tested,
and none absorbed appreciably at 400 nm.Isothermal Titration Calorimetry of PCB 18 and TTR
A 25 M solution of compound 18 (in 10 mM phosphate [pH 7.6],
100 mM KCl, 1 mM EDTA, 8% DMSO) was titrated into a 1.2 M
solution of TTR in an identical buffer using a Microcal MCS Isother-
mal Titration Calorimeter (Microcal, Northampton, MA). An initial
injection of 2 µl was followed by 25 injections of 10 µl at 25°C. The
thermogram was integrated, and a blank was subtracted to yield a
binding isotherm that fit best to a model of two identical binding
sites using the ITC data analysis package in ORIGIN 5.0 (Microcal).
Crystallization and X-Ray Data Collection
Crystals of recombinant WT TTR were obtained from protein solu-
tions at 5 mg/ml (in 100 mM KCl, 100 mM phosphate [pH 7.4], 1 M
ammonium sulfate) equilibrated against 2 M ammonium sulfate in
hanging drop experiments. The TTR•ligand complexes were pre-
pared from crystals soaked for 2 weeks with a 10-fold molar excess
of the ligand to ensure saturation of both binding sites. 1:1 ace-
tone:water solution was used as a soaking agent. A DIP2030b im-
aging plate system (MAC Science, Yokohama, Japan) coupled to
an RU200 rotating anode X-ray generator was used for data collec-
tion. The crystals were placed in paratone oil as a cryo-protectant
and cooled to 120 K for the diffraction experiments. Crystals of all
TTR•ligand complexes are isomorphous with the apo crystal form
containing unit cell dimensions a = 43 Å, b = 86 Å, and c = 65 Å, α,
β, γ = 90°. They belong to the space group P21212 and contain half
of the homotetramer in the asymmetric unit. Data were reduced
with DENZO and SCALEPACK [78].
Structure Determination and Refinement
The protein atomic coordinates for TTR from the Protein Data Bank
(accession number 1BMZ) were used as a starting model for the
refinement of native TTR and the TTR-ligand complexes by molec-
ular dynamics and energy minimization using the program CNS
[79]. Maps were calculated from diffraction data collected on TTR
crystals either soaked with PCBs or cocrystalized simultaneously.
For the complexes of TTR with the PCBs, the resulting maps re-
vealed approximate positions of the ligand in both binding pockets
of the TTR tetramer, with peak heights of above 5–9 rms. In order
to improve the small molecule electron density and remove the
model bias, the model was subjected to several cycles of the shake/
warp protocol [80–82], which resulted in improvement in the map,
especially around the inhibitor. Subsequent model fitting was done
using these maps, and the ligand molecule was placed into the
density. In all three cases, the minimum-energy conformation of the
inhibitor calculated by the program InsightII (Accelrys) was in good
agreement with the bound conformation reflected by the map. Be-
cause of the 2-fold crystallographic symmetry axis along the bind-
ing channel, a statistical disorder model must be applied, giving
rise to two ligand binding modes in each of the two binding sites
of tetrameric TTR. Water molecules were added based upon the
unbiased electron density map. Because of the lack of interpret-
able electron densities in the final map, the nine N-terminal and
three C-terminal residues were not included in the final model. See
Table 2 for a summary of the crystallographic analysis.
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